A Retrospective Study of 291 Patients With Head and Neck Sarcomas:Treatment, Outcomes, and Prognostic Factors

被引:2
作者
Hikmet, R. G. [1 ]
Klug, T. E. [2 ]
Gade, S. D. [3 ]
Sandfeld-Paulsen, B. [4 ]
Aggerholm-Pedersen, N. [5 ,6 ]
机构
[1] Aarhus Univ, Fac Hlth, Vennelyst Blvd 4, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Palle Juul Jensens Blvd 99, DK-998200 Aarhus N, Denmark
[3] Viborg Reg Hosp, Dept Clin Biochem, Heibergs 5A, DK-8800 Viborg, Denmark
[4] Aarhus Univ, Dept Clin Med, Vennelyst Blvd 4, DK-8000 Aarhus C, Denmark
[5] Aarhus Univ Hosp, Dept Expt Oncol, Palle Juul Jensen Blvd 99, DK-8200 Aarhus N, Denmark
[6] Aarhus Univ Hosp, Dept Clin Oncol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark
关键词
SOFT-TISSUE SARCOMA; OSTEOSARCOMA; EXTREMITIES; SURVIVAL; TRUNK; BONE; INFLAMMATION; MORTALITY; CANCER;
D O I
10.1016/j.clon.2024.04.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: Sarcomas constitute a group of rare malignant neoplasms, commonly subcategorized into soft tissue sarcomas (STS) and bone sarcomas. This study aims to describe the treatment modalities and outcome of head and neck sarcoma (HNS) patients in western Denmark and to identify prognostic factors for overall survival and recurrence in HNS patients. Materials and methods: The Aarhus sarcoma registry, The National Danish Sarcoma Database, and the Danish National Pathology Registry were used to identify HNS adult patients diagnosed between 1979 and 2022. Results: Altogether, 291 patients were included in this study. The prevalent histological subtypes were undifferentiated pleomorphic sarcoma (16%; 48/291) and leiomyosarcoma (15%; 44/291) for STS patients (n = 230) and chondrosarcoma (10%; 28/291) and osteosarcoma (7%; 19/291) for bone sarcoma patients (n = 61). Surgery with curative intent was performed in 71% (164/230) and 70% (43/61) of STS and bone sarcoma patients, respectively. Clear resection was achieved in 59% (97/164) of STS patients and 44% (19/43) of bone sarcoma patients. Eighty-nine patients relapsed (STS n = 66, bone sarcoma n = 23) after a median time of 2.7/5.5 years for STS/bone sarcoma patients. The five-year overall survival rates were 45% for STS patients and 66% for bone sarcoma patients. The following factors were significantly, negatively associated with overall survival in STS patients: Age (hazard ratio (HR)) = 1.02, p < 0.001), tumour size ≥5 cm (HR = 1.75, p = 0.003), metastatic disease (HR = 3.17, p < 0.001), high grade tumour (HR = 2.24, p = 0.004), previous cancer (HR = 2.84, p < 0.001), and high Aarhus composite biomarker score (ACBS) (HR = 4.56, p = 0.001). For relapse in STS patients, higher tumour grade (HR = 3.19, p = 0.014), intralesional margins (HR = 2.84, p < 0.001), ≥2 previous cancers (HR = 3.00, p = 0.004), and high ACBS (HR = 3.29, p = 0.047), were negatively associated. For bone sarcomas only higher age (HR = 1.02, p = 0.049) and intralesional margins (HR = 2.91, p = 0.042) were significant negative factors for overall survival. Conclusion: Multiple prognostic factors for overall survival and relapse were identified, especially for STS patients. © 2024 The Author(s)
引用
收藏
页码:409 / 419
页数:11
相关论文
共 43 条
[1]   Serum Biomarkers as Prognostic Factors for Metastatic Sarcoma [J].
Aggerholm-Pedersen, N. ;
Maretty-Kongstad, K. ;
Keller, J. ;
Safwat, A. .
CLINICAL ONCOLOGY, 2019, 31 (04) :242-249
[2]   The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma [J].
Aggerholm-Pedersen, Ninna ;
Maretty-Kongstad, Katja ;
Keller, Johnny ;
Baerentzen, Steen ;
Safwat, Akmal .
TRANSLATIONAL ONCOLOGY, 2016, 9 (04) :322-328
[3]  
Allam A, 1999, Sarcoma, V3, P11, DOI 10.1080/13577149977811
[4]  
[Anonymous], 2002, PDQ Cancer Information Summaries
[5]   Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols [J].
Bielack, SS ;
Kempf-Bielack, B ;
Delling, G ;
Exner, GU ;
Flege, S ;
Helmke, K ;
Kotz, R ;
Salzer-Kuntschik, M ;
Werner, M ;
Winkelmann, W ;
Zoubek, A ;
Jürgens, H ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :776-790
[6]   Managing sarcoma: where have we come from and where are we going? [J].
Bleloch, Jenna S. ;
Ballim, Reyna D. ;
Kimani, Serah ;
Parkes, Jeannette ;
Panieri, Eugenio ;
Willmer, Tarryn ;
Prince, Sharon .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (10) :637-659
[7]   Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors [J].
Callegaro, Dario ;
Miceli, Rosalba ;
Bonvalot, Sylvie ;
Ferguson, Peter C. ;
Strauss, Dirk C. ;
van Praag, Veroniek V. M. ;
Levy, Antonin ;
Griffin, Anthony M. ;
Hayes, Andrew J. ;
Stacchiotti, Silvia ;
Le Pechoux, Cecile ;
Smith, Myles J. ;
Fiore, Marco ;
Tos, Angelo Paolo Dei ;
Smith, Henry G. ;
Catton, Charles ;
Szkandera, Joanna ;
Leithner, Andreas ;
van de Sande, Michiel A. J. ;
Casali, Paolo G. ;
Wunder, Jay S. ;
Gronchi, Alessandro .
ECLINICALMEDICINE, 2019, 17
[8]   Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis [J].
Callegaro, Dario ;
Miceli, Rosalba ;
Bonvalot, Sylvie ;
Ferguson, Peter ;
Strauss, Dirk C. ;
Levy, Antonin ;
Griffin, Anthony ;
Hayes, Andrew J. ;
Stacchiotti, Silvia ;
Le Pechoux, Cecile ;
Smith, Myles J. ;
Fiore, Marco ;
Dei Tos, Angelo P. ;
Smith, Henry G. ;
Mariani, Luigi ;
Wunder, Jay S. ;
Pollock, Raphael E. ;
Casali, Paolo G. ;
Gronchi, Alessandro .
LANCET ONCOLOGY, 2016, 17 (05) :671-680
[9]  
Cancer Research UK, Bone sarcoma incidence statistics 2022
[10]  
Chang AE, 2014, Otolaryngology-Head and Neck Surgery, V151, P976, DOI [10.1177/019459, DOI 10.1177/019459]